secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rein Therapeutics, Inc. (RNTX)
CIK:        0001420565
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001193125-25-120824
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rein Therapeutics Q1 net loss $5.5M; Phase 2 IPF trial initiated
----------------------------------------------------------------

- Net loss $5.5M ($0.25/shr) vs $7.1M ($0.86/shr) year ago; revenue not reported.
- Cash $7.4M at Mar 31, plus $5.28M from April warrant/private placement; runway to Sep 2025.
- Phase 2 RENEW trial of LTI-03 in IPF initiated; topline interim data expected H1 2026.
- Two U.S. patents granted for LTI-03 dry powder formulation (Apr 22, 2025).
- R&D expense $3.1M, G&A $2.5M, both down vs prior year on lower legal and LTI-01 costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420565/000119312525120824/0001193125-25-120824-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420565/000119312525120824/d889805d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-120824

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer